Back to top
more

Eton Pharmaceuticals (ETON)

(Delayed Data from NSDQ)

$3.71 USD

3.71
61,060

-0.04 (-1.07%)

Updated May 3, 2024 04:00 PM ET

After-Market: $3.70 -0.01 (-0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 42.86% and -19.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) Stock Jumps 5.4%: Will It Continue to Soar?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Do Options Traders Know Something About Eton Pharmaceuticals (ETON) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Eton Pharmaceuticals (ETON) stock based on the movements in the options market lately.

Eton Pharmaceuticals, Inc. (ETON) Surges 6.7%: Indication of Further Gains?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Meet Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 0.00% and -1.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Eton Pharmaceuticals, Inc. (ETON): Can Its 13.1% Jump Turn into More Strength?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -23.08% and -92.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 15th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.

ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

by Zacks Equity Research

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag

by Zacks Equity Research

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

Bausch Acquires License for Myopia Solution from Eyenovia

by Zacks Equity Research

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Eton Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Eton Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 17.86% and -93.85%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -108.33% and -93.89%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals Inc (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Eton Pharmaceuticals Inc (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Eton Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Eton Pharmaceuticals

Company News for Mar 30, 2020

by Zacks Equity Research

Companies in the news are: ETON, SDC, RRTS, BKYI

Eton Pharmaceuticals, Inc. (ETON) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.